

CF Foundation Patient Registry Variable List

The CF Foundation Patient Registry variable list is organized into the following sections:

- Demographics
- Diagnosis
- Clinic Visits
- Clinical Measurements
- <u>Microbiology</u>
- Treatments
- Complications
- Care Episodes (Hospitalizations/ Home IV)

Notes:

- Any variable that includes a date or other identifying information is considered protected health information (PHI, highlighted in yellow) and will require an Information Use Agreement in order to be included for approved projects.
- CFF provides encounter-level OR annualized data.
- Variables added after 2018 are in purple.

Please submit all data requests through the online portal: Patient Registry Data Requests | CF Foundation

Questions? Please contact datarequests@cff.org.

I. Variable type: DEMOGRAPHICS

- Birth characteristics
 - Date of birth (mm/dd/yyyy) [PHI]
 - Year of birth
 - Patient's sex
 - State of birth
 - Height of baby in cm
 - o Weight of baby in kg
 - o Baby delivered (full term, premature, unknown)
 - Specify gestational age if under 37 weeks
 - Patient attended day care during this reporting year
- Race / Ethnicity
 - o Race includes 'White'
 - o Race includes 'Black or African American'
 - o Race includes 'American Indian or Alaska Native'
 - o Race includes 'Asian'
 - o Race includes 'Native Hawaiian or Other Pacific Islander'
 - o Race includes 'Some other race'
 - o Patient is Hispanic
- Mortality and Transplant
 - Date of Death (if died) [PHI]
 - Year of death (if died)
 - Reason for death (if died)
 - Age at death [PHI]
 - Date of first lung transplant [PHI]
- Health insurance
 - Health insurance policy (i.e. private insurance)
 - Medicare
 - Medicaid
 - o State special needs program (BCMH, CCS, CRS, GHPP...)
 - TriCare or other military health plan
 - o Indian Health Service
 - Other health insurance
 - o Patient has no health insurance for the entire year
 - o Patient covered on their parents' insurance plan
 - o Receives free medicine/assistance from patient assistance program

Residence

- Patient resides in the US permanently
- Patient state of residence [PHI]
- Program state used for resident state [PHI]
- Current zip code [PHI]
- Socioeconomic characteristics
 - Patient's education
 - Spouse's education
 - Total combined household income before taxes
 - Number of people currently living in household
 - Marital Status
 - Employed part time
 - o Full time homemaker

- o Employed full time
- Unemployed Student
- o Disabled
- o Retired
- Employment unknown
- Smoking
 - o Patient smokes cigarettes during the reporting year
 - o How often was this patient exposed to secondhand smoke
 - o Patient lives in household where someone smokes
- Parent characteristics
 - o Patient's mother's height in cm
 - o Patient's father's height in cm
 - o Father's education
 - Mother's education
- Research involvement
 - o Patient participated in interventional (drug) studies
 - o Patient participated in observational studies
- Patient pregnancy
 - o Patient was pregnant during the reporting year
 - Outcome of patient's pregnancy

II. Variable type: DIAGNOSIS

- Diagnosis date
 - Diagnosis date [PHI]
 - Patient diagnosis
 - Age at diagnosis
 - Year of CF diagnosis
 - o First year in the CFF Patient Registry
- Sweat test
 - Date of last sweat test [PHI]
 - Year of last sweat test
 - First reported sweat test date [PHI]
 - Latest sweat value reported
 - Highest sweat value reported
- Genotyping
 - Has this patient been genotyped
 - Date of genotyping [PHI]
 - Year of last genotyped
 - Mutation classification
 - Name of the first mutation
 - Mutation 1 Class
 - o Poly T tract associated with mutation 1
 - Poly TG repeats mutation 1
 - Name of the second mutation
 - o Mutation 2 Class
 - Poly T tract associated with mutation 2
 - Poly TG repeats mutation 2
 - o Does patient have additional mutations?
 - o Delta F508
- Diagnosis characteristics
 - Meconium ileus with or without perforation
 - Patient diagnosed after false-negative newborn screen
 - o CF dx sugg by Acute or persistent respiratory abnormalities
 - CF dx sugg by CBAVD or related abnormalities
 - o CF dx sugg by Digital clubbing
 - CF dx sugg by DNA Analysis
 - CF dx sugg by Edema
 - CF dx sugg by Electrolyte imbalance
 - o CF dx sugg by Failure to thrive/malnutrition
 - CF dx sugg by Family history
 - CF dx sugg by Infertility/GU abnormalities
 - CF dx sugg by Liver problems
 - o CF dx sugg by Meconium ileus/intestinal obstruction
 - CF dx sugg by Nasal polyps/sinus disease
 - o CF dx sugg by Newborn (neonatal) screening
 - CF dx sugg by Prenatal screening (CVS, amnio)
 - CF dx sugg by Rectal prolapse
 - o CF dx sugg by Steatorrhea/abnormal stool/malabsorption
 - CF dx sugg by Other
 - CF dx sugg by unknown
 - Sweat<60, dx sugg DNA Analysis/genotyping

- o Sweat<60, dx sugg Transepithelial potential differences
- o Sweat<60, dx sugg Clinical presentation
- Sweat<60, dx sugg unknown

III. Variable type: CLINIC VISITS

- Visit details
 - o Site ID
 - Date of Encounter [PHI]
 - o Location where patient was seen
 - Encounter age [PHI]
 - Patient was seen by a Social Worker
 - Patient was seen by a Dietitian/Nutritionist
 - Patient seen by a Pharmacist
 - Patient seen by a Respiratory Therapist
 - Patient seen by a Physical Therapist
 - o Patient seen by a Mental Health Coordinator
 - Was there assessment of oral intake
- Clinic visits summarized by calendar year
 - o # of clinic visits in the review year
 - Primary Program ID
 - Non-primary Program reported in the year
 - Patient was seen by a Social Worker
 - o Patient was seen by a Dietitian/Nutritionist
 - o Patient was seen by a Pharmacist
 - o Patient was seen by a Respiratory Therapist
 - Patient was seen by a Physical Therapist
 - o Did the family receive genetic counseling this year
 - Was there assessment of oral intake
 - Patient seen by a Mental Health Coordinator
 - Eve Exam on Annual Form
 - Age on 12/31 of review year [PHI]
 - Any encounter data
 - Any annual data
- Pulmonary exacerbation encounter level
 - Assessment of potential pulmonary exacerbation
 - o Incr. airway clearance, exercise, and/or bronchodilators
 - Oral NON-quinolone antibiotic
 - o Oral quinolone antibiotic (e.g. Cipro, levofloxacin)
 - o Inhaled antibiotic Inhaled antibiotic PLUS Oral NON-quinolone antibiotic
 - o Inhaled antibiotic PLUS Oral quinolone antibiotic
 - Crackles on physical exam
 - None of the above
- Pulmonary exacerbation summarized by calendar year
 - Any pulmonary exacerbation assessment in the year
 - Any pulmonary exacerbation assessment positive in the year
 - # encounters with pulmonary exacerbation assessments: absent
 - # encounters with pulmonary exacerbation assessments: mild exacerbations
 - o # encounters with pulmonary exacerbation assessments: moderate exacerbations
 - o # encounters with pulmonary exacerbation assessments: severe exacerbations
 - o Encounter exacerbation treatment: Incr. airway clearance
 - o Encounter exacerbation treatment: Oral NON-quinolone antibiotic
 - o Encounter exacerbation treatment: Oral quinolone antibiotic
 - o Encounter exacerbation treatment: Inhaled Antibiotic
 - Encounter exacerbation treatment: Inhaled + Oral NON-quinolone antibiotic

- Encounter exacerbation treatment: Inhaled + oral quinolone antibiotic
- o Encounter exacerbation treatment: None of the above
- # of encounters with crackles (rales) on physical exam
- Infant feeding encounter level
 - Type of feeding
 - Infant formula type
 - o Caloric density (20, 22, 24, 27 or 30 cal/oz)
- Infant feeding summarized by calendar year
 - Type of infant feeding: breast milk
 - o Type of infant feeding: breast milk plus formula
 - Type of infant feeding: formula exclusively
 - Type of infant feeding: other food
 - Type of infant feeding: unknown
 - o Infant formula type: Cow's milk
 - o Infant formula type: Soy milk
 - o Infant formula type: Predigested
 - o Infant formula type: Other
 - o Infant formula caloric density: 20 cal/oz
 - o Infant formula caloric density: 22 cal/oz
 - o Infant formula caloric density: 24 cal/oz
 - o Infant formula caloric density: 27 cal/oz
 - o Infant formula caloric density: 30 cal/oz
 - o Infant formula caloric density: other

IV. Variable type: CLINICAL MEASUREMENTS

- Anthropometric measures encounter level
 - Patient's height
 - Original height as report (includes suspect values)
 - Height Percentile
 - Height Percentile Z score (age < 20)
 - Height Percentile based on WHO (age < 2 only)
 - Height-for-age Z score based on WHO (age < 2)
 - o BMI Value
 - o BMI Percentile
 - o Weight-for-Length Percentile
 - Weight for length percentile based on WHO (age < 2 only)
 - Weight-for-height Z score based on WHO (age < 2)
 - Weight of Patient
 - Original weight as report (includes suspect values)
 - Weight Percentile
 - Weight Percentile Z score (age < 20)
 - Weight percentile based on WHO (age < 2 only)
 - Weight-for-age Z score based on WHO (age < 2)
- Anthropometric measures summarized by calendar year
 - # height measurements in the review year
 - o Patient's height
 - o Height Percentile in the review year
 - Height Percentile Z score (age < 20)
 - Height percentile based on WHO (age < 2 only)
 - Height for Age z-score
 - o BMI Value
 - BMI Percentile
 - Weight-for-Length Percentile
 - Weight for length percentile based on WHO (age < 2 only)
 - Weight-for-height Z score based on WHO (age <2)
 - o # weight measurements in the review year
 - Weight of Patient
 - Weight Percentile
 - Weight Percentile Z score (age < 20)
 - Weight percentile based on WHO (age < 2 only)
 - Weight for Age z-score
- Pulmonary function tests encounter level
 - Was impossible to take PFTs
 - o Measure of FVC
 - Predicted Value for FVC using GLI reference equations
 - o Measure of FEV1
 - CF specific FEV1 percentile for kids
 - Predicted Value for FEV1 using GLI reference equations
 - Measure of FEF25-75
 - Predicted Value for FEF25-75 using GLI reference equations
 - Measure of FEV1FVC
 - Predicted Value for FEV1/FEV1 using GLI reference equations

- Pulmonary function tests summarized by calendar year
 - Any pulmonary data completed
 - # unable to perform pulmonary function test
 - o # FVC measurements in the review year
 - Predicted Value for FVC using GLI reference equations
 - o Predicted Value for FEF25-75 using GLI reference equations
 - Measure of FEV1/FVC
 - Predicted Value for FEV1/FVC using GLI reference equations
 - # FEV1 measurements in the review year
 - Predicted Value for FEV1 using GLI reference equations
 - # FEV25-75 measurements in the review year
 - Measure of FEF25-75
 - o Post-Transplant Predicted Value for FEF25-75 using GLI reference equations
 - o Post-Transplant Predicted Value for FEV1 using GLI reference equations
 - Post-Transplant Predicted Value for FEV1/FVC using GLI reference equations
 - o Post-Transplant Predicted Value for FVC using GLI reference equations
- Lab values encounter level
 - WBC count x1,000/microL
 - Platelet Count x1,000/microL
 - o Hemoglobin (grams per deciliter)
 - Serum Creatinine Level (mg/dL)
 - o Alanine Aminotransferase (ALT or SGPT), IU/L
 - Alkaline phosphatase 2 hour blood glucose (mg/dL)
 - o Hgb A1C value, %
 - Fecal elastase value (microg/g of stool)
 - o Liver enzymes drawn (pre-2010) Aspartate aminotransferase
 - Liver Function Tests Albumin
 - o Total bilirubin, mg/dL
 - GGTP (gamma glutamyl transpeptidase), IU/L
 - Random blood glucose (mg/dL)
 - Fasting glucose level (mg/dL)
 - OGTT Fasting glucose level (mg/dL)
 - 1 hour blood glucose (mg/dL)
- Lab values summarized by calendar year
 - Any lab data completed
 - WBC count x1,000/microL
 - Platelet Count x1,000/microL
 - Hemoglobin (grams per deciliter)
 - Serum creatinine level (mg/dL)
 - o Alanine Aminotransferase (ALT or SGPT), IU/L
 - Aspartate aminotransferase
 - o Total bilirubin, mg/dL
 - o GGTP (gamma glutamyl transpeptidase), IU/L
 - Liver enzymes drawn (pre-2010)
 - Random blood glucose (mg/dL)
 - 1 hour blood glucose (mg/dL)
 - Fasting glucose level (mg/dL)
 - OGTT fasting glucose level (mg/dL)
 - 2 hour blood glucose (mg/dL)

- HgbA1C value, %
- Fecal elastase value (microg/g of stool)
- Alkaline phosphatase
- o Albumin
- Screening tests
 - Was chest x-ray performed in the reporting year
 - Was IgE screening performed in the reporting year
 - Liver function tests performed
 - o Fat soluble vitamin levels measured?
 - o Most recent fecal elastase value
 - o Patient screened for anxiety disorder
 - o Patient screened for symptoms of classic depression
 - o DEXA scan for bone density performed in the reporting year
 - DEXA scan result is normal
 - o DEXA scan result is osteopenia
 - DEXA scan result is osteoporosis
 - o DEXA scan result is other
 - DEXA scan result is unknown
 - Colonoscopy performed
 - o Colonoscopy_results

V. Variable type: MICROBIOLOGY

- Bacteria encounter level
 - o Was bacterial culture done?
 - Date of bacterial culture [PHI]
 - Type of specimen (for bacterial culture)
 - Culture results
 - Staphylococcus aureus
 - o MRSA
 - Any Burkholderia Complex species
 - o Resistant to all aminoglycosides tested
 - Resistant to all quinolones tested
 - o Resistant to all beta lactams tested
 - o Multidrug-Resistant P. aeruginosa (MDR-PA) Infection
 - Alcaligenes
 - Stenotrophomonas
 - o MSSA
 - Haemophilus influenzae (any species)
 - Pseudomonas aeruginosa found in the culture
 - Mucoid Pseudomonas aeruginosa
 - Non-mucoid Pseudomonas aeruginosa
 - o Mucoid Pseudomonas aeruginosa status unknown
- Bacteria summarized by calendar year
 - Any respiratory microbiology data completed
 - o Was bacterial culture done?
 - Number of cultures in the year
 - Number of Micro cultures in the vear
 - Number of Myco cultures in the year
 - # respiratory culture type: sputum
 - # respiratory culture type: induced sputum
 - # respiratory culture type: throat/nasal
 - Any Burkholderia Complex species
 - o Resistant to all aminoglycosides tested
 - o Resistant to all quinolones tested
 - o Resistant to all beta lactams tested
 - o Resistant to at least 2 (beta lactams, aminoglycosides, quinolones)
 - Alcaligenes
 - Stenotrophomonas
 - o MSSA
 - Haemophilus influenzae (any species)
 - o Pseudomonas aeruginosa found in the culture
 - o Mucoid Pseudomonas aeruginosa
 - Non-mucoid Pseudomonas aeruginosa
 - o Mucoid Pseudomonas aeruginosa status unknown
 - # respiratory culture type: bronchoscopy
 - o Any culture result: no growth/sterile
 - o Any culture result: normal flora
 - Any culture result: microorganisms
 - o Staphylococcus aureus
 - o MRSA

- Bacteria other frequency
 - o First year Burkholderia species was reported
 - First year b. cepacia was confirmed at ref. lab
- Mycobacteria encounter level
 - o Was mycobacterial culture done?
 - Date of myco culture [PHI]
 - Type of specimen (for mycobacterial culture)
 - Acid-Fast Bacilli Smear
 - Myco culture results
 - Mycobacterial tuberculosis
 - Mycobacterium terrae
 - Mycobacterium other
 - o Mycobacterium abscessus/chelonae
 - Mycobacterium avium complex
 - Mycobacterium fortuitum group
 - Mycobacterium gordonae
 - Mycobacterium kansasii
 - Mycobacterium marinum
- Mycobacteria summarized by calendar year
 - o Was mycobacterial culture done?
 - # mycobacterial culture type: sputum
 - # mycobacterial culture type: induced sputum
 - # mycobacterial culture type: bronchoscopy
 - o Any Acid-Fast Bacilli smear: Positive
 - Any Acid-Fast Bacilli smear: Negative
 - Mycobacterium terrae
 - Mvcobacterium other
 - Mycobacterium abscessus/chelonae
 - Mycobacterium avium complex
 - Mycobacterium fortuitum group
 - Mycobacterium gordonae
 - Mycobacterium kansasii
 - Mycobacterium marinum
 - o Any Acid-Fast Bacilli smear: Not done
 - Any mycobacterial result: no growth/sterile
 - Any mycobacterial result: normal flora
 - Anv mvcobacterial result: microorganisms
 - Nontuberculous mycobacteria pre 2010
 - Mycobacterial tuberculosis
- Fungus encounter level
 - o Aspergillus Candida Scedosporium species
 - Other bacterial or fungal microorganism species, specify
- Fungus summarized by calendar year
 - Aspergillus Candida Scedosporium species
 - o Other bacterial or fungal microorganism species, specify

VI. Variable type: TREATMENTS

- Antibiotics encounter level
 - Tobramycin solution for inhalation (i.e. TOBI)
 - TOBI frequency
 - o TOBI Podhaler
 - TOBI Podhaler Frequency
 - Other inhaled aminoglycoside (e.g. gentamicin, amikacin)
 - Other aminoglycoside frequency
 - Colistin
 - Colistin Frequency
 - o Aztreonam Inhaled
 - Aztreonam frequency
 - Chronic oral macrolide antibiotic
 - Azithromycin
 - Clarithromycin
 - Sulfa
 - Amoxicillin
 - Tetracycline
 - Other oral antibiotic
 - Other chronic oral antibiotic
 - o Quinolone
 - Cephalosporin
 - o Bethkis
 - Bethkis frequency
- Antibiotics summarized by calendar year
 - Tobramycin solution for inhalation (i.e. TOBI)
 - o TOBI 300 mg BID alternate month schedule
 - o TOBI 300 mg BID continuous
 - TOBI Other regimen (different dose or freg)
 - TOBI for Eradication
 - TOBI as needed
 - o TOBI Podhaler
 - o TOBI Podhaler Four 28mg capsules BID alternate month schedule
 - TOBI Podhaler Other regimen (different dose or frequency)
 - TOBI Podhaler for Eradication
 - o TOBI Podhaler as needed
 - o Other inhaled aminoglycoside (e.g. gentamicin, amikacin)
 - o Aminoglycoside alternate month schedule
 - Aminoglycoside Continuous
 - Aminoglycoside Other regimen (different dose or frequency)
 - o Aminoglycoside for Eradication
 - Aminoglycoside as needed
 - Colistin
 - o Colistin alternate month schedule
 - Colistin Continuous
 - o Colistin Other regimen (different dose or frequency)
 - Colistin for Eradication
 - Colistin as needed
 - o Aztreonam 75 mg TID Alternate Month Schedule
 - Aztreonam 75 mg TID Continuous

- o Aztreonam other regimen
- Aztreonam for eradication
- Aztreonam as needed
- Aztreonam Inhaled
- Chronic oral macrolide antibiotic
- Azithromycin
- Tetracycline
- Other oral antibiotic
- Clarithromycin
- Other chronic oral antibiotic
- Quinolone
- Cephalosporin
- o Sulfa
- Amoxicillin
- Bethkis for Eradication
- Bethkis as needed
- o Bethkis
- Bethkis 300 mg BID alternate month schedule
- Bethkis: other regimen (different dose of freq)
- Pulmonary meds encounter level
 - o Not on any chronic pulmonary medications
 - o Dornase alfa (i.e. Pulmozyme)
 - Dornase frequency
 - Acetylcysteine or Mucomist
 - o High-dose ibuprofen (e.g. 25-30 mg/kg)
 - Hypertonic saline
 - Leukotriene modifiers
 - Mast cell stabilizers
 - Antifungals
 - Oral (e.g. prednisone)
 - o Inhaled (e.g. fluticasone, Flovent, budesonide)
 - o Inhaled in combination wth bronchodilator (e.g. Advair)
 - Other Corticosteroids type
 - Other Corticosteroids Total (mg/dose)
 - Other Corticosteroids frequency
 - Hypertonic saline concentration (%)
 - Hypertonic Saline Frequency
 - Short acting anticholinergic
 - Long acting anticholinergic
 - o Combination beta agonist and anticholinergic
 - Beta agonist
 - Theophylline product
 - Short acting beta agonist
 - Long acting beta agonist
 - o Allergic/intolerant to Macrolide antibiotics
 - o Allergic/intolerant to High-dose ibuprofen
 - o Allergic/intolerant to Hypertonic saline
 - Allergic/intolerant to Aztreonam
 - Drug intolerance/allergies for Ivacaftor
 - Drug intolerance/allergies for Ivacaftor Lumacaftor
 - o Drug intolerance/ allergies for Tezacaftor/Ivacaftor (i.e. Symdeko)
 - Drug intolerance/allergies for Elexa/Tez/Iva

- Allergic/intolerant to Dornase alfa
- o Allergic/intolerant to Tobramycin solution for inhalation
- Allergic/intolerant to Colistin
- Pulmonary meds summarized by calendar year
 - Not on any chronic pulmonary medications
 - o Dornase alfa (i.e. Pulmozyme)
 - o Dornase alfa 2.5 mg qd
 - Dornase alfa 2.5 mg BID
 - Dornase alfa: Other regimen (different dose or frequency)
 - Dornase alfa as needed
 - Acetylcysteine or Mucomist
 - High-dose ibuprofen (e.g. 25-30 mg/kg)
 - Oral (e.g. prednisone)
 - o Inhaled (e.g. fluticasone, Flovent, budesonide)
 - o Inhaled combination wth bronchodilator (e.g. Advair)
 - Oral Corticosteroids Types Prednisone
 - Oral Corticosteroids Types Methylprednisolone (Medrol)
 - o Oral Corticosteroids Types Dexamethasone
 - Oral Corticosteroids Types Other
 - Average Oral Corticosteroids Total (mg/dose)
 - Oral Corticosteroids Frequency Short Term (Less Than Two Weeks)
 - o Oral Corticosteroids Frequency Chronic, Low Dose
 - Oral Corticosteroids Frequency Chronic, High Dose
 - o Oral Corticosteroids Frequency Other
 - Leukotriene modifiers
 - Mast cell stabilizers
 - Antifungals
 - Hypertonic saline
 - Hypertonic saline concentration: 1
 - o Hypertonic saline concentration: 2
 - o Hypertonic saline concentration: 3
 - Hypertonic saline concentration: 4
 - o Hypertonic saline concentration: 5
 - Hypertonic saline concentration: 6
 - Hypertonic saline concentration: 7
 - Hypertonic saline concentration: 8
 - o Hypertonic saline frequency: QD
 - Hypertonic saline frequency: BID
 - Hypertonic saline frequency: Other
 - Hypertonic saline frequency as needed
 - Beta agonist
 - Theophylline product
 - Short acting beta agonist
 - Long acting beta agonist
 - Short acting anticholinergic
 - Long acting anticholinergic
 - Combination beta agonist and anticholinergic
 - Drug intolerance/allergies for Dornase alfa
 - Drug intolerance/allergies for tobramycin
 - Drug intolerance/allergies for Colistin

- Drug intolerance/allergies for Macrolide antibiotics
- o Drug intolerance/allergies for High-dose ibuprofen
- o Drug intolerance/allergies for Hypertonic saline
- Drug intolerance/allergies for Aztreonam
- o Drug intolerance/allergies for Ivacaftor
- o Drug intolerance/allergies for Ivacaftor Lumacaftor
- Drug intolerance/allergies for Elexa/Tez/Iva

CFTR modulators - encounter level

- On Ivacaftor medication (VX-770)
- VX770 (Ivacaftor) dosage
- o Ivacaftor/Lumacaftor (i.e., Orkambi)
- Ivacaftor/Lumacaftor (i.e., Orkambi) dosage
- o Triple Combo Combination Therapy, Elexacaftor / Tezacafor / Ivacaftor (i.e., Trikafta)
- o Triple Combo Dose
- First date prescribed a modulator
- First date prescribed Ivacaftor (i.e., Kalydeco)
- o First date prescribed Lumacaftor / Ivacaftor (i.e., Orkambi)
- First date prescribed Tezacaftor / Ivacaftor (i.e., Symdeko)
- First date prescribed Elexacaftor / Tezacafor / Ivacaftor (i.e., Trikafta)
- First date taking Elexacaftor / Tezacafor / Ivacaftor (i.e., Trikafta)

CFTR modulators - summarized by calendar year

- On Ivacaftor medication (VX-770)
- o Ivacaftor 150 mg BID
- Ivacaftor Other regimen
- Ivacaftor/Lumacaftor (i.e., Orkambi)
- Ivacaftor/Lumacaftor Full dose BID
- o Ivacaftor/Lumacaftor Half dose BID
- o Ivacaftor/Lumacaftor Other regimen
- Triple Combo Combination Therapy (i.e. Trikafta)
- Triple Combo Full Dose BID
- o Triple Combo Dose Half Dose BID
- o Triple Combo Dose Other

Other treatments - encounter level

- Patient is taking enzymes
- Lipase Units per Largest Meal
- Lipase Units per Day
- o H2 Blocker
- Proton Pump Inhibitor
- Acid blocker unknown
- GI Other: Ursodeoxycholic acid
- Salt supplementation
- o CF-specific vitamins (i.e. vitamins A, D, E and K)
- o Is patient currently receiving supplemental feeding
- o Supplemental feeding: total parenteral nutrition
- o Supplemental feeding: oral supplementation

- Supplemental feeding: nasogastric tube
- Supplemental feeding: gastrostomy tube/button
- Supplemental feeding: jejunal tube
- Enzyme use with supplemental feeding
- Primary Airway Clearance technique
- Forced expiratory techniques
- o Oscillating PEP
- High frequency chest wall oscillation
- Exercise
- Positive Expiratory Pressure
- Postural drainage with clapping
- Other treatments annual
 - Did patient use oxygen therapy during this year
 - Use non-invasive ventilation
 - Did the patient receive an influenza vaccination
 - Was the patient started on treatment for NTM
 - o Patient given palivizumab (Synagis) this season
 - Patient on growth hormone in the reporting year
- Other treatments summarized by calendar year
 - Not on any chronic pulmonary medications
 - Any medicine data completed
 - Patient is on enzymes
 - o Patient received supplemental feeding during year
 - o Primary airway clearance technique most frequently used
 - Salt supplementation (encounter age < 2)
 - o CF-specific vitamins (i.e. vitamins A, D, E and K)
 - o Any airway clearance technique data completed
 - Heart/lung transplant in review year
 - Kidney Transplant in review year
 - Liver Transplant in review year
 - Bilateral lung transplant in review year
 - Lung Transplant: Lobar/living donor transplant in review year
 - Lung Transplant: Lobar/cadaveric transplant in review year
 - Other Transplant in review year
 - o Supplemental feeding: oral supplementation
 - o Supplemental feeding: nasogastric tube
 - Supplemental feeding: gastrostomy tube/button
 - o Supplemental feeding: jejunal tube
 - Supplemental feeding: total parenteral nutrition
 - No enzymes recommended with tube feeding
 - Yes, enzymes mixed into the formula
 - Yes, enzymes administered directly through the tube (i.e., not into the formula)
 - Yes, enzymes taken by mouth prior to, during and/or after the feeding
 - Yes, formula infused through Relizorb (enzyme cartridge)
 - o Enzymes, other
 - Exercise
 - No primary airway clearance technique
 - o Other primary airway clearance technique: Positive Expiratory Pressure (PEP)

- Postural drainage with clapping (CPT)
- Forced expiratory techniques (e.g. autogenic drainage)
- Oscillating PEP (e.g. Flutter, acapella, IPV)
- High frequency chest wall oscillation (e.g. Vest)
- Oscillating PEP (e.g. Flutter, acapella, IPV)
- High frequency chest wall oscillation (e.g. Vest)
- Airway clearance technique: Exercise Positive Expiratory Pressure (PEP)
- Postural drainage with clapping (CPT)
- Forced expiratory techniques (e.g. autogenic drainage)

Transplant

- Current transplant status (includes prior years)
- First year had a lung transplant Ever
- Bilateral lung transplant Ever
- Heart/lung transplant Ever
- Lung Transplant: Lobar/cadaveric transplant
- o Ever Lung Transplant: Lobar/living donor transplant
- Ever Any lung transplant
- Ever Liver transplant
- Ever Kidney transplant
- Ever Other transplant
- Were there post transplant complications
- o Bronchiolitis obliterans syndrome
- Lympho-proliferative disorder
- Other transplant complications

VII. Variable type: COMPLICATIONS

- CF related diabetes encounter level
 - CFRD Status
 - Retinopathy
 - Microalbuminuria
 - Chronic renal insufficiency
 - o Chronic renal failure requiring dialysis
 - Peripheral neuropathy
- CF related diabetes annual
 - o CFRD status on annual form
 - o Retinal eye exam performed by an ophthalmologist
 - Spot urine sent for albumin/creatinine ratio
 - Was the patient prescribed treatment for CFRD
 - Spot urine sent for albumin/creatinine ratio
 - Was the patient prescribed treatment for CFRD
 - Dietary change
 - Oral hypoglycemic agents
 - o Intermittent insulin (with illness, steroids, etc.)
 - Chronic insulin
 - Any episodes of severe hypoglycemia
 - Retinopathy
 - Microalbuminuria
 - o Chronic renal insufficiency
 - Chronic renal failure requiring dialysis
 - Peripheral neuropathy
- Liver disease encounter level
 - Gall stones
 - o Gall stones, requiring surgery/procedure
 - Liver disease, cirrhosis
 - Esophageal varices
 - Gastric varices
 - o GI bleed related to varices
 - Splenomegaly
 - Hypersplenism
 - Ascites
 - Encephalopathy
 - Acute hepatitis
 - o Acute hepatitis infectious
 - Acute hepatitis non-infectious
 - o Acute hepatitis unknown
 - Liver disease, non-cirrhosis
 - Hepatic Steatosis
 - Liver disease, other Acute liver failure

- Liver disease summarized by calendar year
 - o Gallstones
 - o Gallstones requiring surgery/procedure
 - o Liver disease, cirrhosis
 - Esophageal varices
 - Gastric varices
 - GI bleed related to varices
 - Splenomegaly
 - o Hypersplenism
 - Ascites
 - Encephalopathy
 - Acute hepatitis
 - Acute hepatitis infectious
 - Acute hepatitis non-infectious
 - Acute hepatitis unknown
 - o Liver disease, non-cirrhosis
 - Hepatic steatosis
 - o Liver disease, other
 - o Acute liver failure
 - o Liver enzymes elevated (for years 2003-2009)
- Other complications encounter level
 - o Patient does not have any complications
 - Arthritis/Arthropathy
 - o Bone fracture
 - o Osteopenia
 - Osteoporosis
 - o Allergic Bronchial Pulmonary Aspergillosis
 - o Asthma
 - o Hemoptysis, massive
 - Hemoptysis type
 - o Pneumothorax requiring chest tube
 - Distal intestinal obstruction syndrome
 - Fibrosing colonopathy/colonic stricture
 - o GERD
 - o GI Bleed requiring hospitalization, non-variceal
 - o Pancreatitis
 - Peptic ulcer disease
 - Rectal prolapse
 - History of intestinal or colon surgery
 - Anxiety disorder
 - Cancer confirmed by histology
 - o Depression
 - Hearing loss
 - Hypertension
 - Kidney Stones
 - Nasal polyps requiring surgery
 - Renal failure requiring dialysis
 - Sinus Disease
 - Absence of vas deferens

- Other complications summarized by calendar year
 - No complications
 - Arthritis/Arthropathy
 - Bone fracture
 - o Osteopenia
 - Osteoporosis
 - o Allergic Bronchial Pulmonary Aspergillosis
 - o Asthma
 - Any Hemoptysis
 - o Hemoptysis massive
 - Hemoptysis other
 - o Pneumothorax requiring chest tube
 - o Distal intestinal obstruction syndrome
 - Fibrosing colonopathy/colonic stricture
 - o GERD
 - o GI Bleed requiring hospitalization, non variceal
 - o Pancreatitis
 - Peptic ulcer disease
 - o Rectal prolapse
 - History of intestinal or colon surgery
 - Anxiety disorder
 - Cancer confirmed by histology
 - Depression
 - Hearing loss
 - o Hypertension
 - Kidney stones
 - Nasal polyps requiring surgery
 - Renal failure requiring dialysis
 - o Sinus Disease
 - Absence of vas deferens

VIII. Variable type: CARE EPISODES (HOSPITALIZATIONS/ HOME IV)

Care episodes

- Care center ID
- Start date for care episode [PHI]
- End date for care episode [PHI]
- Location of care episode
- Care Episode Site ID
- Total Nights for care episode
- # nights in hospital
- # nights on home IV
- # nights with reason pulmonary complication
- # home IV nights with reason pulmonary exacerbation
- # hospitalization nights with reason pulmonary exacerbation
- # home IV nights with reason pulmonary complication
- # hospitalization nights with reason pulmonary complication
- # home IV nights with reason GI complications
- # hospitalization nights with reason GI complications
- # home IV nights with reason Transplant related
- # hospitalization nights with reason Transplant related
- # home IV nights with reason sinus infection
- # hospitalization nights with reason sinus infection
- # home IV nights with reason non-Transplant surgery
- # hospitalization nights with reason non-Transplant surgery
- # home IV nights with reason other
- # hospitalization nights with reason other
- # home IV nights with reason unknown
- # hospitalization nights with reason unknown
- o # hospitalization nights with reason NTM
- o # home IV nights with reason NTM

Care episodes - summarized by calendar year

- Any hospitalization in the year
- # hospitalizations (including partial) in year
- # nights in hospital
- o Any home IV in the year
- # nights on home IV
- o Any episode data
- Total # care episodes in the year
- Total # pulmonary exacerbations treated by IV antibiotics
- # nights in hospital for pulmonary exacerbations
- # nights on home IV for pulmonary exacerbations
- o Total # pulmonary exacerbation treated by IV antibiotics (incl unknown)
- # nights hospital for pulmonary exacerbation (incl unknown)
- # nights home IV for pulmonary exacerbation (incl unknown)
- # nights with reason pulmonary complication
- # nights with reason GI complications

- # nights with reason transplant related# nights with reason sinus infection
- o # nights with reason non-transplant surgery
- o # nights with reason other
- o # nights with reason unknown
- # nights with reason NTM